Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses

• Published in: Human gene therapy Vol. 13; no. 13; p. 1571
• Main Authors: Xin, Ke-Qin, Ooki, Takaaki, Mizukami, Hiroaki, Hamajima, Kenji, Okudela, Koji, Hashimoto, Kumiko, Kojima, Yoshitsugu, Jounai, Nao, Kumamoto, Yasuko, Sasaki, Shin, Klinman, Dennis, Ozawa, Keiya, Okuda, Kenji
• Format: Journal Article
• Language: English
• Published: United States 01-09-2002
• Subjects: Acquired Immunodeficiency Syndrome - immunology; Acquired Immunodeficiency Syndrome - prevention & control; Administration, Oral; AIDS Vaccines - administration & dosage; AIDS Vaccines - genetics; Animals; Dependovirus; Gene Products, env - genetics; Gene Products, env - immunology; Genetic Vectors; HIV-1 - genetics; HIV-1 - immunology; Immunity, Mucosal - genetics; Mice; Mice, Inbred BALB C; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - genetics
• ISSN: 1043-0342
• DOI: 10.1089/10430340260201662

Oral vaccines can induce both systemic and mucosal immunity. Mucosal immunity, especially regional cell-mediated immunity, plays an important role in protecting individuals from infectious diseases such as acquired immunodeficiency syndrome. In this study, a recombinant adeno-associated virus vector expressing human immunodeficiency virus type 1 env gene (AAV-HIV) was orally administered to BALB/c mice. Systemic and regional immunity was induced in the mice. Furthermore, the immunization significantly reduced viral load after an intrarectal challenge with a recombinant vaccinia virus expressing HIV env gene. Moreover, we also show that dendritic cells might contribute to the AAV-HIV vector-induced immune responses.